Compartir
Título
Platelet-derived growth factors from a single donor by apheresis and one freeze–thaw cycle for treating medication-related osteonecrosis of the jaw
Autor
Facultad/Centro
Área de conocimiento
Título de la revista
Regenerative Medicine
Número de la revista
12
Cita Bibliográfica
Julia Vidán-Estévez, Fernando Escalante-Barrigón, Sergio Sánchez-Herráez & Jesús Seco-Calvo (2022) Platelet-derived growth factors from a single donor by apheresis and one freeze-thaw cycle for treating medication-related osteonecrosis of the jaw. Regenerative medicine 17 (12) https://doi.org/10.2217/rme-2022-0126
Editorial
Future Medicine
Fecha
2022
ISSN
1746-0751
Resumen
[EN] To assess whether the use of allogeneic platelet-derived growth factors could serve as a feasible, effective and safe biological therapy for the treatment of medication-related osteonecrosis of the jaw (MRONJ). Materials & methods: Patients with multiple myeloma and MRONJ were included and treated with allogeneic platelet-rich plasma, continued for between 6 and 18 weeks (mean: 9). Results: We observed a treatment success rate of 87.5% (p < 0.05). Assessing the association between healing and treatment duration, we observed a statistically significant relationship (χ2 = 8.00; p = 0.018; Cramer’s V = 1), confirming that healing was very closely related to the duration of the treatment. Conclusion: Allogeneic platelet-rich plasma could be a recommended treatment for MRONJ. Future research with a large sample to validate our findings is required.
Materia
Palabras clave
Peer review
SI
URI
DOI
Versión del editor
Aparece en las colecciones
- Artículos [4950]
Ficheros en el ítem
Tamaño:
38.30
xmlui.dri2xhtml.METS-1.0.size-megabytes
Formato:
Adobe PDF